NCT00141258

Pregabalin Epilepsy Add-On Trial

Pregabalin Add-On Titration Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Pregabalin (150 mg - 600 mg/Day) Using a Flexible, Optimized Dose Schedule in Subjects With Partial Seizures

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 178 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of pregabalin as adjunctive therapy, using a flexible, optimized dose schedule with dose adjustment based on clinical response and tolerability, compared to placebo in subjects with partial seizures

Conditions

• Partial Seizures

Interventions

Type	Name	Description
DRUG	pregabalin

Timeline

• Start date: 2005-10-01
• Completion: 2006-08-01
• First posted: 2005-09-01
• Last updated: 2021-01-22

Locations

5 sites across 1 country: South Korea